These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 22828994

  • 1. [New oral anticoagulants for the prevention of stroke. Open questions in geriatric patients].
    Berthold HK.
    Z Gerontol Geriatr; 2012 Aug; 45(6):498-504. PubMed ID: 22828994
    [Abstract] [Full Text] [Related]

  • 2. [New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
    Koziński M, Obońska K, Kubica A, Navarese EP, Kubica J.
    Kardiol Pol; 2012 Aug; 70(10):1053-60. PubMed ID: 23080100
    [No Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
    Skjøth F, Larsen TB, Rasmussen LH, Lip GY.
    Thromb Haemost; 2014 May 05; 111(5):981-8. PubMed ID: 24577485
    [Abstract] [Full Text] [Related]

  • 4. Management of bleeding associated with dabigatran and rivaroxaban: a survey of current practices.
    Baumann Kreuziger LM, Reding MT.
    Thromb Res; 2013 Aug 05; 132(2):e161-3. PubMed ID: 23916381
    [No Abstract] [Full Text] [Related]

  • 5. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
    Steiner T, Böhm M, Dichgans M, Diener HC, Ell C, Endres M, Epple C, Grond M, Laufs U, Nickenig G, Riess H, Röther J, Schellinger PD, Spannagl M, Veltkamp R.
    Clin Res Cardiol; 2013 Jun 05; 102(6):399-412. PubMed ID: 23669868
    [Abstract] [Full Text] [Related]

  • 6. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation.
    Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J.
    Circ Cardiovasc Qual Outcomes; 2012 Jul 01; 5(4):480-6. PubMed ID: 22787066
    [Abstract] [Full Text] [Related]

  • 7. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW, Barillari G.
    J Clin Pharm Ther; 2014 Apr 01; 39(2):118-35. PubMed ID: 24383983
    [Abstract] [Full Text] [Related]

  • 8. What did we learn from new oral anticoagulant treatment?
    Esmon CT.
    Thromb Res; 2012 Oct 01; 130 Suppl 1(Suppl 1):S41-3. PubMed ID: 23026659
    [Abstract] [Full Text] [Related]

  • 9. [Evidence of novel oral anticoagulants (NOAC)].
    Kitazono T.
    Rinsho Shinkeigaku; 2013 Oct 01; 53(11):992-3. PubMed ID: 24291856
    [Abstract] [Full Text] [Related]

  • 10. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.
    Abraham NS, Singh S, Alexander GC, Heien H, Haas LR, Crown W, Shah ND.
    BMJ; 2015 Apr 24; 350():h1857. PubMed ID: 25910928
    [Abstract] [Full Text] [Related]

  • 11. [Stroke prevention in atrial fibrillation : old and new anticoagulants].
    Darius H, Sommer S.
    Herz; 2013 May 24; 38(3):231-8. PubMed ID: 23632424
    [Abstract] [Full Text] [Related]

  • 12. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
    Providência R, Marijon E, Albenque JP, Combes S, Combes N, Jourda F, Hireche H, Morais J, Boveda S.
    Europace; 2014 Aug 24; 16(8):1137-44. PubMed ID: 24550347
    [Abstract] [Full Text] [Related]

  • 13. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
    Berman JP, Halperin JL.
    Hosp Pract (1995); 2013 Feb 24; 41(1):37-48. PubMed ID: 23466966
    [Abstract] [Full Text] [Related]

  • 14. [Rivaroxaban, dabigatran and apixaban: new anticoagulants in operative urology].
    John A, Michel MS.
    Urologe A; 2014 Jun 24; 53(6):893-902; quiz 903. PubMed ID: 24845012
    [Abstract] [Full Text] [Related]

  • 15. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY, Larsen TB, Skjøth F, Rasmussen LH.
    J Am Coll Cardiol; 2012 Aug 21; 60(8):738-46. PubMed ID: 22575324
    [Abstract] [Full Text] [Related]

  • 16. New oral anticoagulants: will they replace warfarin?
    Little JW.
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 May 21; 113(5):575-80. PubMed ID: 22668618
    [Abstract] [Full Text] [Related]

  • 17. [Stroke prevention after stroke in patients with atrial fibrillation: a case-based review].
    Kovács T.
    Orv Hetil; 2014 Oct 19; 155(42):1655-60. PubMed ID: 25305723
    [Abstract] [Full Text] [Related]

  • 18. Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory.
    Blann AD.
    Br J Biomed Sci; 2014 Oct 19; 71(4):158-67. PubMed ID: 25562993
    [Abstract] [Full Text] [Related]

  • 19. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.
    Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.
    Int Angiol; 2012 Aug 19; 31(4):330-9. PubMed ID: 22801398
    [Abstract] [Full Text] [Related]

  • 20. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials.
    Sardar P, Chatterjee S, Lavie CJ, Giri JS, Ghosh J, Mukherjee D, Lip GY.
    Int J Cardiol; 2015 Jan 20; 179():279-87. PubMed ID: 25464465
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.